Skip to content

Study · Randomized controlled trial · 2015

8 results

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.

Holst JJ, Buse JB, Rodbard HW, Linjawi S, Woo VC, Boesgaard TW, Kvist K, Gough SC

Journal of diabetes science and technology6 Oct 2015Cited by 21 (Europe PMC)

PMID26443290 (opens in a new tab)PMCIDPMC4773967 (opens in a new tab)DOI10.1177/1932296815610124 (opens in a new tab)PepBankPUB-26443290
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira decreased the mean postprandial glucose increment from baseline significantly more than insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, the combination of insulin degludec and liraglutide lowered the after-meal blood sugar rise more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose increment (iAUC0-4h) at week 26, meal test
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in PPG increment
    −12.79 mg/dl
    IDegLira vs insulin degludec

    Source sentences

    Summary
    At week 26, IDegLira produced a significantly greater decrease from baseline in mean PPG increment (normalized iAUC0-4h) than insulin degludec (estimated treatment difference [ETD] -12.79 mg/dl [95% CI: -21.08; -4.68], P = .0023)
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, continuous glucose monitoring showed a greater reduction in postprandial glucose increment over all 3 main meals with IDegLira than with insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, glucose monitoring showed a bigger drop in after-meal blood sugar rise with the combination than with insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    DecreasePostprandial glucose increment (iAUC0-4h) over 3 main meals, CGM
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Estimated treatment difference in PPG increment
    −6.13 mg/dl
    IDegLira vs insulin degludec

    Source sentences

    Summary
    CGM indicated a greater reduction in change from baseline in PPG increment (iAUC0-4h) for IDegLira versus insulin degludec over all 3 main meals (ETD -6.13 mg/dl [95% CI: -10.27, -1.98], P = .0047)
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the insulin secretion ratio was greater with IDegLira than with insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, the combination raised the insulin secretion ratio more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin secretion ratio
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Islet protection · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Insulin secretion ratio and static index were greater for IDegLira versus insulin degludec (P = .048 and P = .006, respectively)
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the static index was greater with IDegLira than with insulin degludec alone.

    In plain wordsIn adults with type 2 diabetes, the combination raised the static index of beta cell function more than insulin degludec alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseStatic index
    Study

    n: not reported in source

    Comparator
    Insulin degludec
    Outcome group
    Islet protection · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Insulin secretion ratio and static index were greater for IDegLira versus insulin degludec (P = .048 and P = .006, respectively)
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, IDegLira decreased the postprandial glucose increment by a similar magnitude as liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, the blood sugar rise after a meal fell by a similar amount with the combination and with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    No significant changePostprandial glucose increment (iAUC0-4h) at week 26, meal test
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Estimated treatment difference in PPG increment
    −1.62 mg/dl
    IDegLira vs liraglutide

    Source sentences

    Summary
    a similar magnitude of decrease as liraglutide (ETD -1.62 mg/dl [95% CI: -10.09; 6.67], P = .70).
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, continuous glucose monitoring showed similar reductions in postprandial glucose increment with IDegLira and liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, glucose monitoring showed a similar drop in after-meal blood sugar rise with the combination and with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    No significant changePostprandial glucose increment (iAUC0-4h) over 3 main meals, CGM
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Estimated treatment difference in PPG increment
    −1.8 mg/dl
    IDegLira vs liraglutide

    Source sentences

    Summary
    similar reductions versus liraglutide (ETD -1.80 mg/dl [95% CI: -2.52, 5.95], P = .4122).
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the insulin secretion ratio with IDegLira was similar to that with liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, the insulin secretion ratio with the combination was similar to that with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeInsulin secretion ratio
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Islet protection · Metabolic and weight

    Source sentences

    Summary
    and similar to liraglutide (P = .45 and P = .895, respectively).
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the static index with IDegLira was similar to that with liraglutide alone.

    In plain wordsIn adults with type 2 diabetes, the static index of beta cell function with the combination was similar to that with liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    No significant changeStatic index
    Study

    n: not reported in source

    Comparator
    Liraglutide
    Outcome group
    Islet protection · Metabolic and weight

    Source sentences

    Summary
    and similar to liraglutide (P = .45 and P = .895, respectively).
    2 context sentences
    Summary · context
    We studied the effect of IDegLira versus its components on postprandial glucose (PPG) in type 2 diabetes.
    Summary · context
    In this substudy, 260 (15.6%) of the original 1663 patients with inadequate glycemic control participating in a 26-week, open-label trial (DUAL I) were randomized 2:1:1 to once-daily IDegLira, insulin degludec or liraglutide.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01336023

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 1,66323 May 2011 to 22 Nov 2012

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 19 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.